Department of Psychological and Brain Sciences, Boston University, Boston, Massachusetts.
Sleep Disorders Service and Research Center, Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois.
JAMA Intern Med. 2015 Sep;175(9):1461-72. doi: 10.1001/jamainternmed.2015.3006.
Cognitive behavioral therapy for insomnia (CBT-I) is the most prominent nonpharmacologic treatment for insomnia disorders. Although meta-analyses have examined primary insomnia, less is known about the comparative efficacy of CBT-I on comorbid insomnia.
To examine the efficacy of CBT-I for insomnia comorbid with psychiatric and/or medical conditions for (1) remission from insomnia; (2) self-reported sleep efficiency, sleep onset latency, wake after sleep onset, total sleep time, and subjective sleep quality; and (3) comorbid symptoms.
A systematic search was conducted on June 2, 2014, through PubMed, PsycINFO, the Cochrane Library, and manual searches. Search terms included (1) CBT-I or CBT or cognitive behavioral [and its variations] or behavioral therapy [and its variations] or behavioral sleep medicine or stimulus control or sleep restriction or relaxation therapy or relaxation training or progressive muscle relaxation or paradoxical intention; and (2) insomnia or sleep disturbance.
Studies were included if they were randomized clinical trials with at least one CBT-I arm and had an adult population meeting diagnostic criteria for insomnia as well as a concomitant condition. Inclusion in final analyses (37 studies) was based on consensus between 3 authors' independent screenings.
Data were independently extracted by 2 authors and pooled using a random-effects model. Study quality was independently evaluated by 2 authors using the Cochrane risk of bias assessment tool.
A priori main outcomes (ie, clinical sleep and comorbid outcomes) were derived from sleep diary and other self-report measures.
At posttreatment evaluation, 36.0% of patients who received CBT-I were in remission from insomnia compared with 16.9% of those in control or comparison conditions (pooled odds ratio, 3.28; 95% CI, 2.30-4.68; P < .001). Pretreatment and posttreatment controlled effect sizes were medium to large for most sleep parameters (sleep efficiency: Hedges g = 0.91 [95% CI, 0.74 to 1.08]; sleep onset latency: Hedges g = 0.80 [95% CI, 0.60 to 1.00]; wake after sleep onset: Hedges g = 0.68; sleep quality: Hedges g = 0.84; all P < .001), except total sleep time. Comorbid outcomes yielded a small effect size (Hedges g = 0.39 [95% CI, 0.60-0.98]; P < .001); improvements were greater in psychiatric than in medical populations (Hedges g = 0.20 [95% CI, 0.09-0.30]; χ2 test for interaction = 12.30; P < .001).
Cognitive behavioral therapy for insomnia is efficacious for improving insomnia symptoms and sleep parameters for patients with comorbid insomnia. A small to medium positive effect was found across comorbid outcomes, with larger effects on psychiatric conditions compared with medical conditions. Large-scale studies with more rigorous designs to reduce detection and performance bias are needed to improve the quality of the evidence.
认知行为疗法(CBT-I)是治疗失眠症的最主要的非药物治疗方法。虽然荟萃分析已经研究了原发性失眠症,但对于 CBT-I 对合并失眠症的疗效知之甚少。
研究 CBT-I 对伴有精神和/或医学疾病的失眠症的疗效,包括(1)失眠症的缓解;(2)自我报告的睡眠效率、入睡潜伏期、睡眠后觉醒时间、总睡眠时间和主观睡眠质量;以及(3)合并症症状。
2014 年 6 月 2 日,通过 PubMed、PsycINFO、Cochrane 图书馆和手动搜索进行了系统搜索。搜索词包括(1)CBT-I 或 CBT 或认知行为[及其变体]或行为疗法[及其变体]或行为睡眠医学或刺激控制或睡眠限制或放松疗法或放松训练或渐进性肌肉松弛或矛盾意向;和(2)失眠或睡眠障碍。
如果研究是随机临床试验,并且至少有一个 CBT-I 组,且有一个满足失眠症诊断标准以及合并症的成年人群,则将其纳入研究。最终分析(37 项研究)的纳入基于 3 位作者的共识,由 3 位作者独立筛查。
由两位作者独立提取数据,并使用随机效应模型进行汇总。两位作者使用 Cochrane 风险偏倚评估工具独立评估研究质量。
预先设定的主要结果(即临床睡眠和合并症结果)来自睡眠日记和其他自我报告的测量。
在治疗后评估时,与对照组或比较组(合并比值比,3.28;95%置信区间,2.30-4.68;P<0.001)相比,接受 CBT-I 的患者中有 36.0%的患者失眠症缓解。对于大多数睡眠参数,治疗前和治疗后的对照效果大小为中到大(睡眠效率:Hedges g=0.91[95%置信区间,0.74-1.08];入睡潜伏期:Hedges g=0.80[95%置信区间,0.60-1.00];睡眠后觉醒时间:Hedges g=0.68;睡眠质量:Hedges g=0.84;均 P<0.001),除了总睡眠时间。合并症结果的治疗效果大小为小(Hedges g=0.39[95%置信区间,0.60-0.98];P<0.001);在精神病患者中比在医学患者中改善更大(Hedges g=0.20[95%置信区间,0.09-0.30];χ2检验的交互作用=12.30;P<0.001)。
认知行为疗法(CBT-I)对改善合并失眠症患者的失眠症状和睡眠参数是有效的。在合并症结果中发现了一个小到中等的积极影响,与医学合并症相比,对精神合并症的影响更大。需要进行设计更严格的大规模研究,以减少检测和表现偏差,从而提高证据质量。